{
    "nct_id": "NCT04040348",
    "title": "A Phase I, Prospective, Open-label Trial to Evaluate the Safety, Tolerability and Exploratory Outcomes of Multiple Allogeneic Human Mesenchymal Stem Cells (HMSC) Infusions in Patients With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2025-04-23",
    "description_brief": "The purpose of this research study is to test the safety, possible side effects, and possible effectiveness of mesenchymal stem cell infusions when given to people with a diagnosis of mild to moderate Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "Allogeneic human mesenchymal stem cells (hMSC) \u2014 umbilical cord-derived, IV infusions (approx. 100 million cells per dose)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests repeated infusions of allogeneic human mesenchymal stem cells (hMSC) in people with mild\u2013moderate Alzheimer\u2019s disease, i.e., a cell therapy (biologic) intervention rather than a small molecule or symptomatic cognitive enhancer. \ue200cite\ue202turn0search0\ue201",
        "Act (evidence & mechanism): The registry entry for this Phase I open\u2011label study lists the intervention as umbilical cord-derived allogeneic hMSC administered intravenously (~100 million cells per infusion). This confirms the intervention is a cell biologic (not a drug compound). \ue200cite\ue202turn0search0\ue201",
        "Act (mechanistic context): Mesenchymal stem cells are thought to act via immunomodulatory, neurotrophic and neuroprotective/paracrine mechanisms (reducing neuroinflammation, secreting growth factors) rather than acting as a small\u2011molecule enzyme inhibitor \u2014 supporting classification as a biologic intended to modify disease processes. \ue200cite\ue202turn0search4\ue202turn0search7\ue201",
        "Reflect (classification rationale and ambiguity): By the provided category definitions, this is best classified as a \"disease\u2011targeted biologic\" because it is a biologic cell therapy intended to treat Alzheimer\u2019s disease pathology/progression. Note: MSCs do not necessarily target amyloid or tau directly (mechanism is broader immunomodulation/neuroprotection), so if the definition were restricted only to biologics that directly target amyloid/tau (e.g., monoclonal antibodies), an alternate label could be debated \u2014 however under the given definitions (biologics targeting AD pathology), cell therapy fits the \"disease\u2011targeted biologic\" category. \ue200cite\ue202turn0search3\ue202turn0search4\ue201"
    ],
    "agent_type": "F) Inflammation",
    "explanation_agent": [
        "Reason: The intervention is allogeneic umbilical cord\u2011derived mesenchymal stem cells (hMSC) given IV; the primary, well\u2011described mechanistic rationale for MSCs in AD is immunomodulation / reduction of neuroinflammation (plus paracrine neurotrophic effects). This aligns best with CADRO category F (Inflammation). \ue200cite\ue202turn0search3\ue202turn1search5\ue201",
        "Act: Evidence from the trial registry entry matches the user description (allogeneic umbilical cord hMSC, IV, ~100 million cells per infusion, repeated dosing). MSCs are repeatedly described in the literature to act via immunomodulatory, anti\u2011inflammatory, and paracrine/neurotrophic mechanisms rather than a single-molecule target (e.g., amyloid or tau antibody). Based on those mechanisms, I assign F) Inflammation as the most specific CADRO match while noting additional neuroprotective/paracrine effects. \ue200cite\ue202turn0search3\ue202turn1search3\ue202turn1search7\ue201",
        "Reflect: MSC therapy is multi\u2011mechanistic (immunomodulation, secretion of growth factors, neuroprotection, altered apoptosis/autophagy), so one could also argue for secondary links to L) Growth Factors and Hormones or M) Synaptic Plasticity/Neuroprotection. However, the dominant, consistently reported action in AD models and MSC reviews is modulation of neuroinflammation, so F) Inflammation is the best single CADRO category. If a strictly multi\u2011target label were required, R) Multi\u2011target would be defensible \u2014 but given the emphasis on immunomodulation in the trial rationale, I selected F. \ue200cite\ue202turn1search5\ue202turn1search9\ue201",
        "Web sources used (key supporting references): 1) Trial registry entry describing the IV umbilical cord\u2011derived allogeneic hMSC intervention (~100 million cells per dose). \ue200cite\ue202turn0search3\ue201 2) Phase I/clinical reports of intraventricular and stereotactic hUCB\u2011MSC trials in AD (examples of clinical MSC use in AD). \ue200cite\ue202turn0search4\ue202turn0search1\ue201 3) Reviews and primary studies summarizing MSC mechanisms \u2014 immunomodulation, paracrine secretion of neurotrophic factors, reduction of neuroinflammation and effects on amyloid/tau in models. \ue200cite\ue202turn1search5\ue202turn1search3\ue202turn1search7\ue201"
    ]
}